Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Postmenopausal Estrogen Use and Parkinson's Disease with and without Dementia
Neurol 50:1141-1143, Marder,K.,et al, 1998
An Unusual Case of Creutzfeldt-Jakob Disease
Neurol 51:617-619, Vingerhoets,F.J.G.,et al, 1998
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
Dopa-Responsive Dystonia, Some Pieces of the Puzzle are Still Missing
Neurol 50:853-855, Nygaard,T.G.&Wooten,G.F., 1998
Hereditary Form of Parkinsonism-Dementia
Ann Neurol 43:768-781, Muenter,M.D.,et al, 1998
The Risk of Parkinson's Disease with Exposure to Pesticides, Farming, Well Water, and Rural Living
Neurol 50:1346-1350, Gorell,J.M.,et al, 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Functional Neurosurgery for parkinson's Disease, Has Come a Long Way, Though Much Remains Experimental
BMJ 316:1259-1260, Quinn,N.&Bhatia,K., 1998
Pallidotomy for Parkinson's Disease:Hitting the Target
Lancet 351:998-999, Golbe,L.I., 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Clinical Usefulness of Magnetic Resonance Imaging in Multiple System Atrophy
JNNP 65:65-71, Schrag,A.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Effect of Selegiline on Mortality in Patients with Parkinson's Disease
Neurol 51:825-830, Olanow,C.W.,et al, 1998
Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Ropinirole for the Treatment of Early Parkinson Disease
Arch Neurol 55:1211-1216, Sethi,K.D.,et al, 1998
Natural History & Survival of 14 Pts with Corticobasal Degeneration Confirmed as Postmortem Exam
JNNP 64:184-189, Wenning,G.K.,et al, 1998
Subcutaneous Apomorphine in Parkinson's Disease
Effective Yet Underused, BMJ 316:6411998., , 1998
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Visual Fields in Patients with Posterior GPi Pallidotomy
Neurol 50:258-265, Biousse,V.,et al, 1998
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Long-Term Follow-Up of Levodopa Responsiveness in Generalized Dystonia
Arch Neurol 55:1320-1323, Dewey,R.B.,et al, 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease
NEJM 337:1036-1042, Lang,A.E.,et al, 1997
Chemosensory Event-Related Potentials in Response to Trigeminal & Olfactory Stim in Idio Parkinson's Dis
Neurol 49:1424-1431, Barz,S.,et al, 1997
Olfactory Dysfunction in Familial Parkinsonism
Neurol 49:1262-1267, Markopoulou,K.,et al, 1997
Smoking and Parkinson's Disease, An Age-Dependent Risk Effect
Neurol 49:1267-1272, Tzourio,C.,et al, 1997
Pallidal Stimulation for Parkinson's Disease, Two Targets
Neurol 49:1564-1569, Bejjani,B.,et al, 1997
Frontotemporal Degeneration, Pick Disease, and Corticobasal Degeneration
Arch Neurol 54:1425-1427, 14291997., Neary,D., 1997
Frontotemporal Dementia, Pick Disease, and Corticobasal Degeneration
Arch Neurol 54:1427-1429, Kertesz,A., 1997
Clozapine in Parkinson's Disase Tremor, Effets of Acute and Chronic Administration
Neurol 49:1587-1590, Bonuccelli,U.,et al, 1997
Occupational Exposures to Metals as Risk Factors for Parkinson's Disease
Neurol 48:650-658, Gorell,J.M.,et al, 1997
Gabapentin for Parkinsonism:A Double-Blind Placebo-Controlled, Crossover Trial
Am J med 102:60-66, Olson,W.L.,et al, 1997
A Gene for Parkinson Disease
Arch Neurol 54:1156-1157, Chase,T.N., 1997
Dietary Antioxidants and Parkinson Disease
Arch Neurol 54:762-765, deRijk,M.C.,et al, 1997
What is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy
Arch Neurol 54:937-944, Litvan,I.,et al, 1997
Olfactory Dysfunction in Parkinson's Disease
JNNP 62:436-446, Hawkes,C.H.,et al, 1997
Neurological Signs and Frontal White Matter Lesions in Vascular Parkinsonism
Stroke 28:965-969, Yamanouchi,H.&Nagura,H., 1997
Distinction of Idiopathic Parkinson's Dis from Multi-Syst Atrophy by Stim of Growth-Hormone Release w Clonidine
Lancet 349:1877-1881, Kimber,J.R.,et al, 1997